ABBOTT PARK, Ill., June 22, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the French health authority has approved the expansion of reimbursement coverage for its FreeStyle Libre 2 ...

ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...

Abbott Diabetes Care is recalling certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors due to falsely low glucose readings.

Abbott Laboratories ABT recently announced that the FreeStyle Libre 2 system's reimbursement coverage has been expanded by the French health authority to cover individuals using basal insulin as part ...

Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...

Please provide your email address to receive an email when new articles are posted on . A voluntary medical device correction warned users of three Abbott FreeStyle Libre readers about the risk of ...

Abbott Laboratories received U.S. FDA clearance for the Freestyle Libre 2 and Freestyle Libre 3 continuous glucose monitoring (CGM) sensors for integration with automated insulin delivery (AID) ...

Tandem’s Control-IQTM hybrid closed-loop technology now integrates with the 15-day continuous glucose monitoring sensor. This ad will auto-close in 10 seconds ...

Abbott Laboratories has initiated a voluntary medical device correction pertaining to its FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Readers, stating that a limited number of ...

A year after joining forces with a goal of improving health management for people with Type 2 diabetes, Abbott and WeightWatchers’ partnership has borne fruit. The pair has now officially launched ...

At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, the agency’s strongest, ...

First and only continuous glucose monitoring system to be nationally reimbursed in France for people who use once-daily (basal) insulin 1 Expanded reimbursement facilitates wider access to continuous ...